Factor Viii

In this video, Lindsey A. George, MD, discussed updated clinical trial data around hemophilia gene therapy presented at ASH Annual Meeting and Exposition.

In this video interview with Healio, Lindsey A. George, MD, spoke about a session on factor VIII biochemistry presented at ASH Annual Meeting and Exposition.

In this video, Lindsey A. George, MD, talked about improving the function of factor VIII variants for hemophilia A gene therapy, which she presented in a session at ASH Annual Meeting and Exposition.

Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe hemophilia A, according to phase 3 study results published in The New England Journal of Medicine.

Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and factor VIII concentrate use relative to factor VIII prophylaxis in patients with severe hemophilia A, according to study results.

The novel gene therapy SPK-8011 induced sustained factor VIII expression in patients with hemophilia A, according to results of a nonrandomized phase 1/phase 2 dose-escalation study published in The New England Journal of Medicine.

An IV injection of BIVV001 induced high sustained factor VIII activity levels among men with severe hemophilia A, according to results of a phase 1/phase 2 open-label trial published in The New England Journal of Medicine.

ORLANDO, Fla. — In this video at the ASH Annual Meeting and Exposition, Steven W. Pipe, MD, professor of pediatrics and pathology at the University of Michigan, reviews recent innovations in hemophilia and incorporating gene therapy into practice.

The FDA has granted orphan drug designation to SIG-001, an investigational therapy under evaluation for hemophilia A, according to a press release from the drug’s manufacturer.